Contrast enhancement of brain tumors and irradiated normal brain: a comparison of iohexol and iothalamate.
The nonionic contrast agent iohexol was compared with the ionic agent iothalamate for contrast enhancement of brain tumors and radiation brain damage in dogs. Tissue enhancement during infusion of contrast and 5, 10, 15 and 30 min later was measured using quantitative computed tomography. Blood iodine was measured using x-ray fluorescence. Peak contrast enhancement occurred during infusion in tumors and after 5 min in irradiated normal brain for both contrast agents. Absolute uptake of contrast in each lesion was the same for both agents when normalized to total grams of iodine administered. Blood iodine levels were slightly but not significantly higher using iohexol. The reduced osmotic load and similar contrast enhancement of lesions suggest that the nonionic contrast medium iohexol may be a useful agent for routine CT of the brain.
D000818:Animals; D001921:Brain / Q000528:radiation effects*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging*; D004285:Dogs; D004806:Ependymoma / Q000000981:diagnostic imaging; D007457:Iodine Radioisotopes / Q000009:adverse effects*; D007463:Iodobenzoates; D007472:Iohexol; D007482:Iothalamate Meglumine; D007483:Iothalamic Acid; D008297:Male; D008577:Meningeal Neoplasms / Q000000981:diagnostic imaging; D008579:Meningioma / Q000000981:diagnostic imaging; D011833:Radiation Injuries, Experimental / Q000000981:diagnostic imaging*; D014057:Tomography, X-Ray Computed; D014283:Triiodobenzoic Acids
D007457:Iodine Radioisotopes; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007483:Iothalamic Acid; D007472:Iohexol; D007482:Iothalamate Meglumine